Despite the high frequency of PIK3CA mutations in breast cancers, the response to PI3K inhibitor therapy has been more challenging than expected, and the prognostic significance of detecting somatic PIK3CA mutations in breast tumors is unclear22. This evidence concerns the gene PIK3CA and breast neoplasm.